Weight Loss$89.99–$799

SLU-PP-332: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 6 sources cited

Overview

SLU-PP-332 is a small-molecule agonist of the estrogen-related receptor (ERR) family, particularly ERRα, ERRβ, and ERRγ. Dubbed an 'exercise mimetic,' it activates the same transcriptional programs induced by endurance exercise — mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber gene expression. In preclinical studies, it dramatically improved exercise endurance and fatigue resistance without physical training.

Mechanism of Action

SLU-PP-332 activates the estrogen-related receptors (ERRs), a family of orphan nuclear receptors that serve as master regulators of energy metabolism. Despite their name, ERRs do not bind estrogen — they regulate genes involved in mitochondrial biogenesis (PGC-1α, NRF1, TFAM), oxidative phosphorylation, fatty acid oxidation (CPT1, MCAD, VLCAD), and the tricarboxylic acid cycle. ERRα is the predominant isoform in skeletal muscle, heart, and brown adipose tissue. By activating ERRs, SLU-PP-332 upregulates the transcription of hundreds of metabolic genes simultaneously, effectively reprogramming muscle fibers toward a more oxidative (slow-twitch) phenotype. This increases mitochondrial density, enhances lipid utilization over glucose, and improves fatigue resistance. In a skeletal muscle cell line the compound increased mitochondrial function and cellular respiration, and in obese mice it raised whole-body energy expenditure and fatty acid oxidation.

SLU-PP-332 Benefits: What the Research Shows

  • A 2023 study in ACS Chemical Biology showed SLU-PP-332 increased type IIa oxidative muscle fibres and enhanced treadmill exercise endurance in mice, with ERRα activation required for the effect
  • Treated mice showed an acute aerobic exercise gene program, and in a skeletal muscle cell line the compound increased mitochondrial function and cellular respiration
  • Muscle fibre analysis in treated mice showed an increase in type IIa oxidative fibres
  • In diet-induced obese and ob/ob mice, SLU-PP-332 raised energy expenditure and fatty acid oxidation, reduced fat mass and improved insulin sensitivity
  • Developed by Thomas Burris's group at the Center for Clinical Pharmacology, Washington University School of Medicine in St. Louis, published in 2023

SLU-PP-332 Dosage

  • Preclinical dose: 25–50 mg/kg administered intraperitoneally in mice (not directly translatable to humans)
  • No established human dosing protocol — compound is in preclinical research phase
  • Research protocols typically involve daily administration for 4–8 weeks
  • SLU-PP-332 lacks oral bioavailability and was given by intraperitoneal injection in the mouse studies; a later analogue, SLU-PP-915, is the orally active one
  • May be combined with physical exercise for potentially synergistic effects on endurance
  • Human-equivalent dose estimation suggests 2–4 mg/kg orally, but this is speculative
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

SLU-PP-332 Side Effects & Safety

Known Side Effects

  • No human safety data available — all data is from preclinical models
  • The mouse studies measured metabolic and exercise outcomes rather than safety endpoints, and no toxicology study of SLU-PP-332 has been published
  • Theoretical concern about cardiac effects given ERR expression in heart tissue
  • Potential hormonal effects due to structural similarity to estrogen-related receptors, though ERRs do not bind estrogen
  • Unknown long-term effects on muscle fiber composition and metabolic flexibility

Safety Profile

SLU-PP-332 is an early-stage research compound with no human clinical data. No rodent toxicology study of SLU-PP-332 has been published; the mouse work reports metabolic and exercise outcomes, not safety endpoints, and no trial has been registered in humans. The ERR receptor family is expressed in multiple tissues including heart, liver, kidney, and brain, raising the possibility of off-target metabolic effects. Long-term consequences of forced mitochondrial biogenesis and fiber-type switching are unknown. This compound should be considered strictly experimental. Not recommended for human use until Phase I safety data becomes available.

What to Expect

No human experience data exists. In preclinical models, effects on exercise endurance are observed within 2–4 weeks of daily administration. Mitochondrial biogenesis and fiber-type changes occur gradually over weeks. If human effects mirror rodent data, one might expect improved exercise endurance, reduced fatigue, enhanced fat utilization during exercise, and improved recovery — essentially mimicking the adaptations of a structured endurance training program. However, without human data, all expectations are speculative.

Common Stacks

Storage & Handling

Store as dry powder at -20°C, protected from light and moisture. Once dissolved in appropriate vehicle (DMSO for research use), aliquot and store at -20°C. Avoid repeated freeze-thaw cycles. Shelf life of dry powder is approximately 2 years when stored properly. Solution stability varies by vehicle — use freshly prepared solutions when possible.

Pricing & Available Variants

$89.99 – $799price range
0.5mg/ML1mg/ML100mg x 30100mg x 120

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023.
  2. Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024.
  3. Billon C, Appourchaux K, Côté I, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026.
  4. Okda HE, Zhao P, Hayes M, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. Int J Biol Macromol. 2026.
  5. Registered studies of SLU-PP-332. ClinicalTrials.gov. 2026.
  6. Radwan MO, Guin S, Burris TP. Pharmacology of estrogen-related receptors (ERRs) agonists. RSC Chem Biol. 2026.

Related Peptides

Track SLU-PP-332 in Your Protocol

Log your SLU-PP-332 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free